- Oral
- Injectable
Churg Strauss Syndrome Market size was valued at USD 357.4 million in 2022 and is expected to reach USD 486.4 million by 2029, at a CAGR of 4.5% from 2023 to 2029. Patients with Churg Strauss Syndrome are given prednisone, methylprednisolone, or another immunosuppressive corticosteroid drug, which is a generic pharmaceutical. The Five Factor Score (FFS) for each patient determines the medicine for Churg Strauss Syndrome. According to NORD, the estimated mean annual incidence of churg strauss syndrome is 2.4 individuals per million and can affect individuals of almost any age and has ranged from 15 to 70 years of age. Moreover, most the researchers say that the disease is undiagnosed and leads to many complications in the future years. However, lack of awareness reading autoimmune disorders and unfavorable reimbursement policies are expected to hinder the growth of the market over the future years.The report studies global churg strauss syndrome market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global churg strauss syndrome market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
owing to increasing prevalence of churg strauss syndrome and other allergic reactions and asthma and rising incidence of churg strauss syndrome in children drives the growth of the churg strauss syndrome market over the forecast period.
The acupuncture market size was valued at USD 357.4 million in 2022
The acupuncture market key players are: Heron Therapeutics, Inc. Silvergate Grifols GlaxoSmithKline Roxane Laboratories, Inc. Hikma Pharmaceutical Corp. Rx Pharma Novartis Schein Pharmaceutical Inc.
The churg strauss syndrome market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.